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In a recent article in Nature, Muthusami et al.1 highlight the
promiscuity of serine palmitoyltransferase (SPT) for non-essential
amino acids under low serine conditions, illustrating a previously
unappreciated mechanism for inhibition of tumour growth—
increased levels of deoxysphingolipids.
Tumour cells acquire a range of metabolic adaptations, driven
directly and indirectly by genetic mutations, making altered
cellular metabolism a hallmark of cancer.2 Metabolic rewiring
drives tumour progression by allowing cancer cells to take
advantage of and shape their niche in order to command a
constant nutrient supply. However, cancer-specific metabolic
adaptations also introduce vulnerabilities that can be exploited
clinically. Since the implementation over a half-century ago of
chemotherapeutic anti-metabolite drugs such as methotrexate, a
folate cycle inhibitor, new pharmacological approaches focussed
on targeting metabolic pathways are in trial, and, recently, novel
defined dietary regimens aimed to aid cancer therapy have come
to the fore.3 In particular, modulation of serine and glycine
availability is proven to be effective in inhibiting the growth of
specific subtypes of tumour in vivo.4 These non-essential amino
acids, which can be synthesised from glucose, are pivotal
substrates for several metabolic pathways, including the biosynth-
esis of proteins and nucleic acids. However, the molecular
mechanism behind the ability of serine-free diet to restrict tumour
growth, with respect to alteration in the cancer lipodome remains
uncharted. In a recent publication in Nature, Muthusami et al.1
explore the effect of tumour serine restriction on sphingolipid
heterogeneity, highlighting the promiscuity of SPT as a metabolic
liability of cancer cells that can be exploited through diet or
pharmacological means.
The authors began by comparing the metabolic changes
induced in cancer cell lines by attachment-independent (spheroid)
growth, finding increased secretion and intracellular accumulation
of alanine along with a decreased flux through the pyruvate
dehydrogenase enzyme. Since previous reports have shown that
inhibition of the mitochondrial pyruvate carrier (MPC) is able to
decrease alanine levels in adherent cultured cells, to further
investigate the correlation between the alanine accumulation and
altered mitochondrial metabolism, Muthusami et al.1 performed
[U-13C6]glucose and [2,3-
13C2]alanine tracing in both adherent and
spheroid cultures. Interestingly, upon MPC inhibition or knock-
down, the authors observed that spheroid growth was boosted,
secretion/accumulation of alanine was rescued and serine
synthesis increased. Specifically, the authors demonstrated in
spheroid cultures that while glucose metabolism was diverted
towards the serine synthesis pathway, alanine flux into the TCA
cycle was increased, bypassing the inactivity of MPC. Hence,
Muthusami et al.1 hypothesised that alanine could be deleterious
for anchorage-independent growth; the authors showed that the
advantage given by the lack of the MPC was abrogated by
exogenous alanine supplementation. Likewise, a comparable
effect was achieved by serine/glycine depletion, suggesting a
connection between the two events.
To further elucidate the mechanism by which serine restriction
impaired spheroid growth, Muthusami et al.1 compared the
kinetics of different serine-consuming enzymes and SPT displayed
a Km within intratumoral serine concentrations, thus limiting its
affinity for serine in serine-restricted conditions. Under normal
conditions SPT catalyses sphingosine synthesis using serine as a
substrate. However, SPT displays substrate promiscuity, and
during serine restriction can switch to alanine (Fig. 1). Using
alanine, SPT generates 1-deoxysphinganine, a precursor of 1-
deoxydihydroceramide (deoxyDHCER) and 1-deoxyceramide
(deoxyCER). By either exogenous supplementation of those lipids
or inhibition of their metabolism at different stages, the authors
elegantly demonstrated that the negative growth phenotype
observed in the serine-starved spheroids culture was, at least in
part, due to toxicity of deoxyCER.
Next, the authors investigated this newly identified vulnerability
in the context of in vivo physiology using xenograft models
coupled with pharmacological and dietary intervention. In
similarity to recent studies, the authors demonstrated that upon
serine and glycine starvation tumour progression was significantly
decreased.4 Mechanistically this was accompanied by an increase
in toxic deoxysphingolipids, similar to the in vitro phenotype
initially shown, whereas other canonical sphingolipids maintained
stable levels. Intriguingly, deoxysphingolipids increased to a lesser
extent in healthy tissues, such as the liver, indicating that the
tumour cells are more prone to produce and retain the toxic lipid
species than normal cells. Additionally, the authors also reported
decreased levels of lactosylceramide (d18:1/d16:0), a precursor of
complex membrane lipids, suggesting an altered membrane
composition. Furthermore, the authors showed increased expres-
sion of the liver enzymes involved in alanine degradation,
suggesting putative alanine scavenging activity of the liver and
prevention of the accumulation of toxic lipid species.
To validate the proposed mechanism, Muthusami et al.1 rescued
in vivo tumour growth by inhibiting SPT concurrent with a serine
and glycine-restricted diet. While at high dose the SPT inhibitor
displayed a systemic harmful effect, at lower drug concentration
the authors observed stable liver function and restored xenograft
growth despite limited serine availability. Finally, the authors
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employed an alternative means to decrease serine availability, by
administering a phosphoglycerate dehydrogenase (PHGDH, first
enzyme of the serine synthesis pathway) inhibitor that signifi-
cantly reduced both plasma and tumour levels of serine and
glycine concomitantly with toxic deoxysphingolipid accumulation.
This study has elegantly highlighted the possibility of exploiting
promiscuous enzymes such as SPT to treat cancer by limiting the
availability of the primary substrate, leading to the production of
toxic lipid species, altering cellular membrane composition and
ultimately impairing tumour growth. Importantly, it was demon-
strated that tumour cells were more susceptible to this interven-
tion than healthy tissues, giving a clear therapeutic window for this
approach. Given the importance of several other serine/glycine-
dependent pathways in cancer cell metabolism,5 such as protein
synthesis, folate-dependent one-carbon metabolism (for nucleo-
tide synthesis) and glutathione synthesis, it seems likely that toxic
metabolite accumulation is one of several metabolic outcomes of
serine and glycine limitation that could contribute concurrently to
impeding tumour growth. It is technically challenging to dissect
the exact contribution of each process as inhibiting/supplementing
one metabolic pathway will likely modulate the serine availability
for use by alternate pathways, making it difficult to isolate the
importance of any individual pathway. Interestingly, the promis-
cuity of SPT is not limited to serine and alanine, but also to
palmitoyl-CoA and other acyl-CoA species, suggesting a more
intricate and complex network of stress signals via tuning cellular
lipid diversity that could prompt further research for new therapies.
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Fig. 1 SPT promiscuity links intra-tumoral serine and alanine metabolism to sphingolipid heterogeneity in cancer cells. Schematic diagram
depicting sphingolipid synthesis under normal (left, blue) and low serine (red, right) conditions. Under normal conditions serine
palmitoyltransferase (SPT) synthesises sphingosine (SO) as the canonical precursor of dihydroceramide (DHCER), ceramide (CER) and
ultimately complex membrane lipids. Under low serine conditions alanine is an SPT substrate, fuelling synthesis of 1-deoxysphinganine
(deoxySA), which is further metabolised into 1-deoxydihydroceramide (deoxyDHCER) and 1-deoxyceramide (deoxyCER), altering membrane
lipid diversity and impairing tumour growth
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